Vendor Intelligence Report: Steady Meds

Published 13 Jun 2026. 22-page investigative report on who is behind Steady Meds: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Steady Meds is a narrow-evidence vendor, not a catalog-wide known quantity. Across 8 Finnrick lab tests the overall pass rate is 88%: 7 pass / 1 fail. All tests are Retatrutide. That gives buyers one usable signal, but the record includes a no-Retatrutide failure and methodology-sensitive ratings.

That product-specific nuance matters because the storefront advertises a 100-SKU peptide and injectable catalog: GLP-1s, HGH-axis products, BPC-157, TB-500, HCG, blends, and supplies. Finnrick evidence should not be extrapolated across it. Retatrutide is better evidenced than the rest of Steady Meds, yet still not a clean-choice record.

The operator record adds friction. The site omits a legal entity, physical address, named officer, or filled-out privacy controller; Wayback, privacy-shielded registration, and archive artifacts point to a recently assembled storefront on a reused domain. Off-site brand pages, a ShopAgg/Hong Kong infrastructure trail, and a spread of North American WhatsApp numbers support a China-linked export-storefront read.

The report also separates COA appearance from vial assurance. A reviewed BPC-157 document is a bulk-powder certificate with Chinese personnel names and no named independent lab, address, or accreditation. Thin but negative review evidence adds a fulfillment-risk layer through specific non-delivery and fake-tracking allegations, without converting those complaints into a statistical rate.

Inside the full report:

  • Per-product pass/fail rate, sample-level Retatrutide record, and methodology-divergence chart
  • Dated domain-reuse timeline using Wayback captures and RDAP records
  • ShopAgg/Hong Kong infrastructure and reverse-IP export-site analysis
  • BPC-157 bulk-COA review with batch/date and personnel artifacts
  • WhatsApp/contact mapping, registry dead ends, and corporate-identity omissions
  • Trustpilot, Peptigrity, automated scanner, and affiliate-promotion sweep

Risk assessment

  • Undisclosed offshore operation and corporate-anonymity risk — high: No legal entity, address, or responsible personnel are disclosed; RDAP is privacy-shielded, while Facebook, hosting, and ShopAgg evidence indicate a China-linked export operation.
  • Retatrutide quality and supply-chain risk — high: Retatrutide is the only Finnrick-tested product: 8 tests, 7 pass / 1 fail, 82.15% rating; the failed sample reportedly contained no Retatrutide.
  • COA and documentation-integrity risk — high: Reviewed BPC-157 COA is a 998.0g bulk-powder document with no named lab, address, accreditation, or retail-vial chain-of-custody assurance.
  • Shipping and fulfillment-reliability risk — medium: Two May 2026 Trustpilot reviews allege fake tracking, non-delivery, and scam behavior; sample size is small but specific.